Clinical Trial Update: Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a dendritic cell/tumor fusion vaccine with interleukin-12 for breast cancer was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dendritic cell/tumor fusion vaccine with interleukin-12 (dendritic cell/tumor fusion vaccine plus IL-12)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-03-16